• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 81Survival outcomes: RFA compared with TACE-RFA, randomized controlled trial

Study
Rating
Design
Treatment Group
N
InterventionSurvival Time FromMedian OS (95% CI)% Survival Year 1% Survival Year 2% Survival Year 3% Survival Year 4% Survival Year 5Statistical Comparison
Morimoto et al. 201092
37
Poor
RCT
TACE-RFA
19
TACE with epirubicin (30–50 mg per body surface), lipiodol, and gelatin sponge particles via hepatic artery followed by percutaneous RFA with multitined expandable electrode or internally cooled electrode followedRandomizationNR1009393NRNRNS,
p=0.369
RFA
18
Percutaneous RFA with multitined expandable electrode or internally cooled electrodeRandomizationNR898980NRNR

Abbreviations: CI = confidence interval; N = number of patients; NR = not reported; NS = nonsignificant; OS = overall survival; RCT = randomized controlled trial; RFA = radiofrequency ablation; TACE = transarterial chemoembolization.

From: Results

Cover of Local Therapies for Unresectable Primary Hepatocellular Carcinoma
Local Therapies for Unresectable Primary Hepatocellular Carcinoma [Internet].
Comparative Effectiveness Reviews, No. 114.
Belinson S, Yang Y, Chopra R, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.